← Back to Clinical Trials
Recruiting NCT06142448

NCT06142448 The Effect of Compensation Strategies on Gait Impairment in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06142448
Status Recruiting
Phase
Sponsor Radboud University Medical Center
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 384 participants
Start Date 2023-12-01
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cueing app

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 384 participants in total. It began in 2023-12-01 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Gait disturbances are disabling and common in Parkinson's disease (PD). Patients use many different, and typically self-developed, strategies to compensate for their walking abnormalities. There is a wide variety of compensatory strategies, of which external and internal cueing are the most commonly known. External cueing refers to externally produced predictive stimuli such as a metronome, whereas internal cueing refers to a movement reference generated internally, such as counting while walking. The efficacy of external and internal cueing varies dramatically across patients, and some patients can even be identified as 'non-responders' to a particular cue. Consequently, a one-size-fits-all approach simply does not suffice, which increases the need for better understanding of the key mechanisms behind these compensation strategies. Furthermore, it is still unknown how the efficacy of compensation strategies changes longitudinally. The goal of the UNITE-PD project is to address these questions. The investigators aim to investigate whether the efficacy of internal and external cueing changes over time, and whether it is differentially affected in responders and non-responders. In order to work towards a more personalized treatment for patients with PD, the investigators also aim to identify potential patient characteristics that can mediate the actual use of compensation strategies in daily life. The multicenter UNITE-PD project is divided in a joint package and individual site-specific packages. All partners will investigate the neural working mechanisms of compensation strategies in PD from different angles in the site-specific packages. The joint package focusses on the long-term effect of the compensation strategies and the potential patient characteristics that can influence the efficacy of the compensation strategies. In this project, the investigators will define responders and non-responders to external and/or internal cueing. With the use of extensive clinimetrics, the aim is to identify patient characteristics that might influence the efficacy. With the use of a custom made cueing app (which will be applied during a follow up period of six months), the long-term effect of cueing in the responders can be investigated. Together, all centers aim to include a total of 384 participants (Netherlands N = 104, Belgium N =90, Israel N = 75, Italy N = 115). Importantly, this sample size is not based on the joint workpackage described here, but on the numbers needed for the individual site-specific work packages.

Eligibility Criteria

Inclusion Criteria: * Men and women of age \> 18 years with idiopathic Parkinson's disease; * Written informed consent. Exclusion Criteria: * Daily usage of compensation strategies for the past month; * Presence of deep brain stimulation (DBS); * Presence of severe co-morbidity limiting ambulation (e.g. stroke, orthopaedic problems); * Inability to walk unaided (with the exception of a customary cane); * Inability to walk for \> 3 minutes consecutively; * Severe auditory impairments, hampering perception of auditory cues; * Severe cognitive impairment (MMSE \< 21)

Contact & Investigator

Central Contact

Cindel Albers

✉ cindel.albers@radboudumc.nl

📞 (024) 366 84 26

Frequently Asked Questions

Who can join the NCT06142448 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06142448 currently recruiting?

Yes, NCT06142448 is actively recruiting participants. Contact the research team at cindel.albers@radboudumc.nl for enrollment information.

Where is the NCT06142448 trial being conducted?

This trial is being conducted at Nijmegen, Netherlands.

Who is sponsoring the NCT06142448 clinical trial?

NCT06142448 is sponsored by Radboud University Medical Center. The trial plans to enroll 384 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology